  0 Table of Contents |
  1 Home |
| 2 2022 CDC Clinical Practice Guideline - Profiles |
| 3 2022 CDC Clinical Practice Guideline - Terminology |
| 4 2022 CDC Clinical Practice Guideline - Examples |
 5 2022 CDC Clinical Practice Guideline - Documentation |
 5.1 2022 CDC Clinical Practice Guideline - Implementation Documentation |
| 5.2 2022 CDC Clinical Practice Guideline - Integration Documentation |
| 5.3 2022 CDC Clinical Practice Guideline - Process Documentation |
 5.4 2022 CDC Clinical Practice Guideline - Service Documentation |
| 6 2022 CDC Clinical Practice Guideline - Downloads |
| 7 2022 CDC Clinical Practice Guideline - Subroutines |
| 8 2022 CDC Clinical Practice Guideline - Acute Pain |
| 9 2022 CDC Clinical Practice Guideline - Quick Start |
| 10 Chronic Pain Decision Documentation |
| 11 Recommendation #1 - Nonpharmacologic and Nonopioid Pharmacologic Therapy Consideration |
| 12 Recommendation #2 - Prioritize Nonopioid Pain Therapies |
| 13 Recommendation #3 - Opioid Immediate Release Form When Starting Opioid Therapy |
| 14 Recommendations #4 and #5 - Lowest Effective Dose |
| 15 Recommendation #6 - Prescribe Lowest Effective Dose and Duration |
| 16 Recommendation #7 - Opioid Therapy Risk Assessment |
| 17 Recommendation #8 - Naloxone Consideration |
| 18 Recommendation #9 - Consider Patient's History of Controlled Substance Prescriptions |
| 19 Recommendation #10 - Urine Drug Testing |
| 20 Recommendation #11 - Concurrent Use of Opioids and Benzodiazepines |
| 21 Recommendation #12 - Evidence-based Treatment for Patients with Opioid Use Disorder |
| 22 License and Legal Terms |
 23 Artifacts Summary |
 23.1 HelloWorld |
| 23.2 HelloWorldPatientView |
| 23.3 CDCMMEClinicalConversionFactors |
| 23.4 OpioidCDSRoutines |
| 23.5 OpioidCDSCommon |
| 23.6 OpioidCDSCommonConfig |
| 23.7 OpioidLogicMK2020 |
| 23.8 OpioidData2020 |
| 23.9 FHIRHelpers |
| 23.10 FHIRModelInfo |
| 23.11 OpioidCDSREC10CommonLibrary |
| 23.12 OpioidCDSREC01Library |
| 23.13 OpioidCDSREC02Library |
| 23.14 OpioidCDSREC03Library |
| 23.15 OpioidCDSREC04And05Library |
| 23.16 OpioidCDSREC06Library |
| 23.17 OpioidCDSREC07Library |
| 23.18 OpioidCDSREC08Library |
| 23.19 OpioidCDSREC09Library |
| 23.20 OpioidCDSREC10Library |
| 23.21 OpioidCDSREC10PatientViewLibrary |
| 23.22 OpioidCDSREC11Library |
| 23.23 OpioidCDSREC11PatientViewLibrary |
| 23.24 OpioidCDSREC12PatientViewLibrary |
| 23.25 OpioidRiskAssessmentActivityDefinition |
| 23.26 OpioidUrineScreeningActivityDefinition |
| 23.27 PlanDefinition - 2022 CDC Clinical Practice Guideline for Prescribing Opioids for Pain: Recommendation #1 |
| 23.27.1 Library |
| 23.28 PlanDefinition - 2022 CDC Clinical Practice Guideline for Prescribing Opioids for Pain: Recommendation #2 |
| 23.28.1 Library |
| 23.29 PlanDefinition - 2022 CDC Clinical Practice Guideline for Prescribing Opioids for Pain: Recommendation #3 |
| 23.29.1 Library |
| 23.30 PlanDefinition - 2022 CDC Clinical Practice Guideline for Prescribing Opioids for Pain: Recommendations #4 and #5 |
| 23.30.1 Library |
| 23.31 PlanDefinition - 2022 CDC Clinical Practice Guideline for Prescribing Opioids for Pain: Recommendation #6 |
| 23.31.1 Library |
| 23.32 PlanDefinition - 2022 CDC Clinical Practice Guideline for Prescribing Opioids for Pain: Recommendation #7 |
| 23.32.1 Library |
| 23.33 PlanDefinition - 2022 CDC Clinical Practice Guideline for Prescribing Opioids for Pain: Recommendation #8 (order-sign) |
| 23.33.1 Library |
| 23.34 PlanDefinition - 2022 CDC Clinical Practice Guideline for Prescribing Opioids for Pain: Recommendation #8 |
| 23.34.1 Library |
| 23.35 PlanDefinition - 2022 CDC Clinical Practice Guideline for Prescribing Opioids for Pain: Recommendation #9 |
| 23.35.1 Library |
| 23.36 PlanDefinition - 2022 CDC Clinical Practice Guideline for Prescribing Opioids for Pain: Recommendation #10 (order-sign) |
| 23.36.1 Library |
| 23.37 PlanDefinition - 2022 CDC Clinical Practice Guideline for Prescribing Opioids for Pain: Recommendation #10 (patient-view) |
| 23.37.1 Library |
| 23.38 PlanDefinition - 2022 CDC Clinical Practice Guideline for Prescribing Opioids for Pain: Recommendation #10 |
| 23.38.1 Library |
| 23.39 PlanDefinition - 2022 CDC Clinical Practice Guideline for Prescribing Opioids for Pain: Recommendation #11 (patient-view) |
| 23.39.1 Library |
| 23.40 PlanDefinition - 2022 CDC Clinical Practice Guideline for Prescribing Opioids for Pain: Recommendation #11 |
| 23.40.1 Library |
| 23.41 PlanDefinition - 2022 CDC Clinical Practice Guideline for Prescribing Opioids for Pain: Recommendation #12 (patient-view) |
| 23.41.1 Library |
| 23.42 Morphine Milligram Equivalent (MME) Conversion Factors for FHIR R4 |
| 23.43 Morphine Milligram Equivalent (MME) Calculator for FHIR R4 |
| 23.44 Opioid Management Terminology Knowledge Data |
| 23.45 Opioid Management Terminology Knowledge Logic |
| 23.46 CDC_CarePlan |
| 23.47 CDC_MedicationRequest |
| 23.48 CDC_Observation |
| 23.49 CDC_RequestGroup |
| 23.50 CDC_ValueSet |
| 23.51 DataDateRollerExtension |
| 23.52 EffectiveDataRequirement Extension |
| 23.53 CDC 2022 Opioid Guidance Clinical Focus Extension |
| 23.54 CDC 2022 Opioid Guidance Data Element Extension |
| 23.55 CDC 2022 Opioid Guidance exclusion Criteria Extension |
| 23.56 CDC 2022 Opioid Guidance Inclusion Criteria Extension |
| 23.57 ValueSet - Medication Request Category Community |
| 23.58 ValueSet - Medication Request Status Active |
| 23.59 CodeSystem - CDC 2022 Opioid Indicator |
| 23.60 OpioidCDS CarePlan |
| 23.61 Cancer Diagnosis Condition |
| 23.62 End of Life Condition |
| 23.63 Terminal Condition |
| 23.64 Cancer Diagnosis Encounter |
| 23.65 Oncology Participant Encounter |
| 23.66 Ambulatory Opioid MedicationDispense |
| 23.67 OpioidCDS MedicationRequest |
| 23.68 Ambulatory Opioid MedicationRequest |
| 23.69 OpioidCDS Observation |
| 23.70 OpioidCDS Patient |
| 23.71 Oncology Specialist PractitionerRole |
| 23.72 OpioidCDS RequestGroup |
| 23.73 Palliative Care ServiceRequest |
| 23.74 Amphetamine-class drugs and metabolite urine tests |
| 23.75 Amphetamine class medications |
| 23.76 Benzodiazepine medications |
| 23.77 Buprenorphine and Methadone medications |
| 23.78 Cannabinoid class urine drug screening |
| 23.79 CDC malignant cancer conditions |
| 23.80 CNS depressant medications |
| 23.81 Cocaine urine drug screening tests |
| 23.82 Sleep disordered breathing |
| 23.83 Conditions documenting substance misuse |
| 23.84 Conditions likely terminal for opioid prescribing |
| 23.85 Extended release opioid with ambulatory misuse potential |
| 23.86 Fentanyl-type medications |
| 23.87 Fentanyl-type urine drug screening tests |
| 23.88 General opiate urine drug screening tests |
| 23.89 Hospice Finding |
| 23.90 Hospice Procedure |
| 23.91 Limited life expectancy conditions |
| 23.92 Methadone urine drug screening tests |
| 23.93 Methadone medications |
| 23.94 Naloxone medications |
| 23.95 Non-opioid drug urine screening |
| 23.96 Non-synthetic opioid medications |
| 23.97 Oncology specialty designations (NUCC) |
| 23.98 Opiate specific urine drug screening tests |
| 23.99 Opioid counseling procedure |
| 23.100 Opioid drug urine screening |
| 23.101 Opioid misuse assessment procedure |
| 23.102 Opioid misuse disorders |
| 23.103 Opioid treatment assessment procedure |
| 23.104 Pain management procedure |
| 23.105 Pain treatment plan |
| 23.106 PDMP data reviewed finding |
| 23.107 PDMP review procedure |
| 23.108 Phencyclidine urine drug screening tests |
| 23.109 Sickle-cell diseases |
| 23.110 Substance misuse behavioral counseling |
| 23.111 Synthetic opioid medications |
| 23.112 Synthetic opioid urine drug screening tests |
| 23.113 Therapies indicating end of life care |
| 23.114 Condition Clinical Status Active |
| 23.115 Encounter Diagnosis Condition Category |
| 23.116 Problem List Condition Category |
| 23.117 US Core Health Concern Condition Category |
| 23.118 Hospice Disposition |
| 23.119 Observation Category Laboratory |
| 23.120 Observation Category Procedure |
| 23.121 Office Visit |
| 23.122 Xylazine drug urine screening tests |
| 23.123 CQFToolingDevice |
|